Effectiveness of Etanercept for Idiopathic Pneumonia Syndrome Following Stem Cell Transplantation (BMT CTN 0403)
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The study is designed as a Phase III, multi-center randomized, double-blind,
placebo-controlled trial investigating the use of etanercept for the treatment of acute,
non-infectious pulmonary dysfunction (IPS) occurring after allogeneic hematopoietic cell
transplantation (HCT).
Phase:
Phase 3
Details
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Collaborators:
Blood and Marrow Transplant Clinical Trials Network National Cancer Institute (NCI) National Marrow Donor Program